Merck's Efinopegdutide Meets Primary Endpoint in Phase 2b MASH Clinical Trial
Merck (MRK) announced that its investigational drug, efinopegdutide, successfully met the primary efficacy endpoint in a Phase 2b clinical trial. The study focused on treating adults suffering from metabolic dysfunction-associated steatohepatitis (MASH) with stage F2 or F3 fibrosis. The trial evaluated various subcutaneous doses of the once-weekly candidate, specifically at levels of 4 mg, 7 mg, and 10 mg. This development represents a significant milestone in Merck's efforts to address high unmet medical needs within the metabolic disease sector.
Tickers: $MRK
Topics: drug efficacy MASH metabolic dysfunction-associated steatohepatitis Phase 2b trial
Read the full article at Seeking Alpha
Part of the story Merck's Efinopegdutide Meets Primary Endpoint in Phase 2b MASH Clinical Trial (2 articles)